12th International p53 Workshop

描述(申请人提供)：P53抑癌蛋白在肿瘤抑制中起关键作用，其基因是人类癌症中最常见的突变。因此，在分子、细胞和生物水平上阐明野生型p53如何在正常细胞中发挥作用，或突变型p53如何在肿瘤细胞中发挥作用，将为人类癌症提供重要的、新颖的治疗和诊断方法。国际P53研讨会不断吸引从事P53研究的科学家互动，讨论他们的最新科学发现，并发起新的合作。这些会议对于促进p53领域的非凡活力具有极其重要和有效的作用。第12届国际P53研讨会将于2004年11月6日至10日在新西兰达尼丁与奥塔哥大学有关的一个会议中心举行。这次会议的地点是为了促进美国和欧洲科学界与包括日本、澳大利亚和新西兰在内的太平洋地区的科学家之间的互动。组织委员会由会议召集人Antony Braithwaite博士(新西兰达尼丁的奥塔哥大学)和Bruce博士组成 Baguley博士(奥克兰癌症学会研究中心，新西兰奥克兰)，Carlos Cordon-Cardo博士(美国纽约斯隆-凯特琳纪念癌症中心)，Curtis Harris博士(美国贝塞斯达人类癌变实验室)，David Lane博士(苏格兰邓迪大学)，Martin Lavin博士(昆士兰研究所医学研究所，澳大利亚布里斯班)，Arnold Levine博士(美国普林斯顿大学高级研究所)，Mohe Oren博士(以色列雷霍沃特魏兹曼科学研究所)，Carol Prives博士(美国哥伦比亚大学，纽约)，Roger del Redves博士(儿童医学研究所，澳大利亚布里斯班)他们是：Varda Rotter博士(以色列雷霍沃特魏兹曼科学研究所)、Janice Royds博士(新西兰奥塔哥大学达尼丁分校)、Thierry Soussi博士(法国巴黎居里研究所)、Yoichi Taya博士(日本东京国立癌症中心研究所)和Thea Tisty博士(美国加州大学旧金山分校)。组委会已经成功地筹集了资金，以支付受邀演讲者的费用。为美国博士后研究员和研究生，包括妇女和代表不足的少数族裔和残疾人的费用申请资金。这种支持对于研讨会的一项关键任务至关重要，即支持对p53和癌症研究界未来美国领导人的科学和培训。

DESCRIPTION (provided by applicant): The p53 tumor suppressor protein plays pivotal roles in tumor suppression and its gene is the most frequently mutated in human cancers. Thus, elucidating at molecular, cell and organismal levels how wild-type p53 functions in normal cells, or how mutant p53 dysfunctions in tumor cells will yield important and novel therapeutic and diagnostic approaches to human cancer. The International p53 Workshops have continuously attracted scientists working on p53 to interact, discuss their latest scientific findings and initiate new collaborations. These meetings have been enormously important and effective for promoting the exceptional vigor of the p53 field. The 12th International p53 Workshop will be held November 6-10 2004 in Dunedin, New Zealand at a conference center associated with the University of Otago. The conference site was chosen this time to facilitate interactions between the US and European scientific communities with scientists from Pacific region including Japan, Australia and New Zealand. The organizing committee consists of the conference convener, Dr Antony Braithwaite (University of Otago, Dunedin, New Zealand) along with Dr Bruce Baguley, (Auckland Cancer Society Research Centre, Auckland, New Zealand), Dr Carlos Cordon-Cardo, (Memorial Sloan-Kettering Cancer Centre, New York, USA) Dr Curtis Harris (Laboratory of Human Carcinogenesis, Bethesda, USA), Dr David Lane (University of Dundee, Dundee, Scotland), Dr Martin Lavin (Queensland Institute Medical Research, Brisbane, Australia), Dr Arnold Levine, (Institute for Advanced Study, Princeton, USA), Dr Moshe Oren (Weizmann Institute of Science, Rehovot, Israel), Dr Carol Prives (Columbia University, New York, USA), Dr Roger Reddel (Children's Medial Research Institute, Sydney, Australia), Dr Varda Rotter (Weizmann Institute of Science, Rehovot,Israel), Dr Janice Royds (University of Otago, Dunedin, New Zealand), Dr Thierry Soussi (Institut Curie, Paris, France), Dr Yoichi Taya (National Cancer Centre Research Institute, Tokoyo, Japan) and Dr Thea Tisty (University of California, San Francisco, USA). The organizing committee has been successful in raising money for covering expenses of invited speakers. Funding is requested for expenses of US postdoctoral fellows and graduate students including women and underrepresented minorities and people with disabilities. This support will be crucial for a key mission of the Workshop, which is to support the science and training of future US leaders in the p53 and cancer research communities.